Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Lexaria Bioscience ( (LEXX) ).
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with a pharmaceutical company to further evaluate its DehydraTECH technology in a pre-clinical setting. This extension allows for continued collaboration and strategic planning as the pharmaceutical company reviews data from Lexaria’s Australian study, with final results expected by the end of 2025. This development could enhance Lexaria’s industry positioning by demonstrating the efficacy and safety of its technology, potentially impacting stakeholders by solidifying partnerships and advancing clinical applications.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology, which enhances the oral delivery of drugs by improving bio-absorption, reducing side effects, and facilitating drug delivery across the blood-brain barrier. The company operates a licensed research laboratory and holds a substantial intellectual property portfolio with 54 patents granted worldwide.
Average Trading Volume: 578,547
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.67M
For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.